,11,48 Pretreatment of SARS-CoV-2 with heparan sulfate or the structurally similar glycosaminoglycan heparin (Figure 4C) inhibited the infection of NCI-H1975 cells via the ACE2- as well as the TMEM106B-dependent route, confirming the capacity of SARS-CoV-2 to bind glycosaminoglycans. Here, TMEM106B is linked to infection.